Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 9/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696273 | 0.98 | SMN1; SMN2 (0.41) | HTR2AHRH1HTR2CDRD2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL48286 | 0.93 | HRH1 (0.39) | HTR2AHRH1HTR2CDRD2ALDH1A1 | |
| SCHEMBL3690635 | 0.83 | HTR2A (0.44) | HTR2AHRH1HTR2CDRD2ALDH1A1 | |
| SCHEMBL13993921 | 0.82 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2CYP1A2MAPK1ATM | |
| SCHEMBL7361325 | 0.81 | HSD17B10 (0.48) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL22557833 | 0.81 | SIGMAR1 (0.45) | HTR2AHRH1HTR2CDRD2ALDH1A1 | |
| SCHEMBL3683753 | 0.81 | ARG1 (0.39) | HTR2AHRH1HTR2CDRD2ALDH1A1 | |
| SCHEMBL13993907 | 0.80 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP1A2MAPK1NPSR1 | |
| SCHEMBL5232657 | 0.80 | L3MBTL1 (0.42) | ALDH1A1SMN1; SMN2CYP1A2MAPK1ATM | |
| SCHEMBL13993911 | 0.80 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP1A2MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925077-A | Pyrido ring compound, and preparation method, intermediate, composition and application thereof | 一又生物(上海)有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-114149428-B | Pyrido ring compound, and preparation method, intermediate, composition and application thereof | 中国药科大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-114149428-A | Pyridine-fused ring compound and preparation method, intermediate, composition and application thereof | 中国药科大学 | 2022-03-08 | — | — | CN | disclosed |
| US-8105760-B2 | Patterning process and pattern surface coating composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090053657-A1 | PATTERNING PROCESS AND PATTERN SURFACE COATING COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | HTR2A 4866/4885HRH1 4024/4885HTR2C 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.